165 related articles for article (PubMed ID: 29331266)
1. Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.
McCormack SE; Cruz CRY; Wright KE; Powell AB; Lang H; Trimble C; Keller MD; Fuchs E; Bollard CM
Cytotherapy; 2018 Mar; 20(3):385-393. PubMed ID: 29331266
[TBL] [Abstract][Full Text] [Related]
2. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
4. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.
Lee SJ; Cho YS; Cho MC; Shim JH; Lee KA; Ko KK; Choe YK; Park SN; Hoshino T; Kim S; Dinarello CA; Yoon DY
J Immunol; 2001 Jul; 167(1):497-504. PubMed ID: 11418688
[TBL] [Abstract][Full Text] [Related]
5. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
[TBL] [Abstract][Full Text] [Related]
6. Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.
DeVoti JA; Steinberg BM; Rosenthal DW; Hatam L; Vambutas A; Abramson AL; Shikowitz MJ; Bonagura VR
Clin Diagn Lab Immunol; 2004 May; 11(3):538-47. PubMed ID: 15138179
[TBL] [Abstract][Full Text] [Related]
7. E6 and E7 fusion immunoglobulin from human papilloma virus 16 induces dendritic cell maturation and antigen specific activation of T helper 1 response.
Kim SH; Hur YJ; Lee SJ; Kim SJ; Park CG; Oh YK; Jung WW; Seo JB; Nam MH; Choi I; Chun T
Biotechnol Lett; 2011 Apr; 33(4):663-71. PubMed ID: 21140193
[TBL] [Abstract][Full Text] [Related]
8. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
Schoell WM; Mirhashemi R; Liu B; Janicek MF; Podack ER; Penalver MA; Averette HE
Gynecol Oncol; 1999 Sep; 74(3):448-55. PubMed ID: 10479508
[TBL] [Abstract][Full Text] [Related]
10. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
11. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy.
Thornburg C; Boczkowski D; Gilboa E; Nair SK
J Immunother; 2000; 23(4):412-8. PubMed ID: 10916750
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
16. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
17. Influence of Human Papillomavirus E7 Oncoprotein on Maturation and Function of Plasmacytoid Dendritic Cells In Vitro.
Han R; Song YJ; Sun SY; Zhou Q; Chen XZ; Zheng QL; Cheng H
Virol Sin; 2018 Dec; 33(6):493-501. PubMed ID: 30569289
[TBL] [Abstract][Full Text] [Related]
18. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
19. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Bartkowiak T; Singh S; Yang G; Galvan G; Haria D; Ai M; Allison JP; Sastry KJ; Curran MA
Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5290-9. PubMed ID: 26351680
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
